Hippocampal abnormalities of glutamate/glutamine, N -acetylaspartate and choline in patients with depression are related to past illness burden
Background Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness. The aim of our study was to investigate metabolite abnormalities in the hippocampus associated with past depressive illness burden. Method...
Gespeichert in:
| Veröffentlicht in: | Journal of psychiatry & neuroscience 2013-03, Vol.38 (2), p.107-116 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 116 |
|---|---|
| container_issue | 2 |
| container_start_page | 107 |
| container_title | Journal of psychiatry & neuroscience |
| container_volume | 38 |
| creator | de Diego-Adeliño, Javier, MD Portella, Maria J., PhD Puigdemont, Dolors, MD Pérez-Egea, Rosario, MD Pérez, Víctor, MD, PhD Gómez-Ansón, Beatriz, MD, PhD López-Moruelo, Olga, BSc Serra-Blasco, Maria, BSc Vives, Yolanda, PhD |
| description | Background Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness. The aim of our study was to investigate metabolite abnormalities in the hippocampus associated with past depressive illness burden. Methods Glutamate/glutamine (Glx), N -acetylaspartate (NAA) and choline (Cho), potential markers of glial/neuronal integrity and membrane turnover, respectively, were measured in adults with depression and healthy controls using a 3 T magnetic resonance spectroscopy scanner. Voxels were placed in the head of the right and left hippocampus. We controlled for systematic differences resulting from volume-of-interest (VOI) tissue composition and total hippocampal volume. Results Our final sample comprised a total of 16 healthy controls and 52 adult patients with depression in different stages of the illness (20 treatment-resistant/chronic, 18 remitted-recurrent and 14 first-episode), comparable for age and sex distribution. Patients with treatment-resistant/chronic and remitted-recurrent depression had significantly lower levels of Glx and NAA than controls, especially in the right hippocampal region ( p ≤ 0.025). Diminished levels of Glx were correlated with longer illness duration (left VOI r = −0.34, p = 0.01). By contrast, Cho levels were significantly higher in patients with treatment-resistant/chronic depression than those with first-episode depression or controls in the right and left hippocampus (up to 19% higher; all p ≤ 0.025) and were consistently related to longer illness duration (right VOI r = 0.30, p = 0.028; left VOI r = 0.38, p = 0.004) and more previous episodes (right VOI r = 0.46, p = 0.001; left VOI r = 0.44, p = 0.001). Limitations The cross-sectional design and the inclusion of treated patients are the main limitations of the study. Conclusion Our results support that metabolite alterations within the hippocampus are more pronounced in patients with a clinical evolution characterized by recurrences and/or chronicity and add further evidence to the potential deleterious effects of stress and depression on this region. |
| doi_str_mv | 10.1503/jpn.110185 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3581591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A320845089</galeid><els_id>1_s2_0_S1180488213500205</els_id><sourcerecordid>A320845089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c722t-e16708d536a279c30051e5258c3d7ef854b050ec08ec9acd2295a1ef20a1599d3</originalsourceid><addsrcrecordid>eNqVk8Fu1DAQhiMEoqVw4QGQBQIBIq3txE1yQaoqoJUqkCicrVlnsuvi2KmdFPoUvDKz2tLuor0gH2Jnvvk91syfZU8F3xeKFwcXg98Xgota3ct2RVnXuSyL8j7tRc1zOsud7FFKF5xzyYV6mO3IopSqUXw3-31ihyEY6AdwDGY-xB6cHS0mFjo2d9MIPYx4sNpZj-_YZ5aDwfHaQRogjhRl4FtmFsFRnFnPBiABPyb2044L1uIQMSUbPIOILKKjlJaNgbg0MuucpzCbTbFF_zh70IFL-OTmu5d9__jh2_FJfvbl0-nx0VluKinHHMVhxetWFYcgq8YUnCuBSqraFG2FXa3KGVccDa_RNGBaKRsFAjvJQaimaYu97P1Kd5hmPbaGyo3g9BBtD_FaB7B6M-LtQs_DlS5UTQqCBF7fCMRwOWEadW-TQefAY5iSFoWQolqWSeiLf9CLMEVPzyNKFbIqD5s1ag4OtfVdoHvNUlQfFZLXpeJ1Q1S-hZqjRyoyeOws_d7gn2_hzWAv9Tq0vwWi1WJvzVbVNxsJxIz4a5zDlJI-Pf_6H-znTfbVGrtAcOMiBRo9Gp60Cb5dgSaGlCJ2t50TXC9NockUemUKgp-t9_oW_esCAl7eAJAMuC6CNzbdcRUJ0c13Q4M0mVcWozY08pZSfuA1pruu6iQ11-dL_y3tR11eWk8VfwCQcSYY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1353274690</pqid></control><display><type>article</type><title>Hippocampal abnormalities of glutamate/glutamine, N -acetylaspartate and choline in patients with depression are related to past illness burden</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>de Diego-Adeliño, Javier, MD ; Portella, Maria J., PhD ; Puigdemont, Dolors, MD ; Pérez-Egea, Rosario, MD ; Pérez, Víctor, MD, PhD ; Gómez-Ansón, Beatriz, MD, PhD ; López-Moruelo, Olga, BSc ; Serra-Blasco, Maria, BSc ; Vives, Yolanda, PhD</creator><creatorcontrib>de Diego-Adeliño, Javier, MD ; Portella, Maria J., PhD ; Puigdemont, Dolors, MD ; Pérez-Egea, Rosario, MD ; Pérez, Víctor, MD, PhD ; Gómez-Ansón, Beatriz, MD, PhD ; López-Moruelo, Olga, BSc ; Serra-Blasco, Maria, BSc ; Vives, Yolanda, PhD</creatorcontrib><description>Background Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness. The aim of our study was to investigate metabolite abnormalities in the hippocampus associated with past depressive illness burden. Methods Glutamate/glutamine (Glx), N -acetylaspartate (NAA) and choline (Cho), potential markers of glial/neuronal integrity and membrane turnover, respectively, were measured in adults with depression and healthy controls using a 3 T magnetic resonance spectroscopy scanner. Voxels were placed in the head of the right and left hippocampus. We controlled for systematic differences resulting from volume-of-interest (VOI) tissue composition and total hippocampal volume. Results Our final sample comprised a total of 16 healthy controls and 52 adult patients with depression in different stages of the illness (20 treatment-resistant/chronic, 18 remitted-recurrent and 14 first-episode), comparable for age and sex distribution. Patients with treatment-resistant/chronic and remitted-recurrent depression had significantly lower levels of Glx and NAA than controls, especially in the right hippocampal region ( p ≤ 0.025). Diminished levels of Glx were correlated with longer illness duration (left VOI r = −0.34, p = 0.01). By contrast, Cho levels were significantly higher in patients with treatment-resistant/chronic depression than those with first-episode depression or controls in the right and left hippocampus (up to 19% higher; all p ≤ 0.025) and were consistently related to longer illness duration (right VOI r = 0.30, p = 0.028; left VOI r = 0.38, p = 0.004) and more previous episodes (right VOI r = 0.46, p = 0.001; left VOI r = 0.44, p = 0.001). Limitations The cross-sectional design and the inclusion of treated patients are the main limitations of the study. Conclusion Our results support that metabolite alterations within the hippocampus are more pronounced in patients with a clinical evolution characterized by recurrences and/or chronicity and add further evidence to the potential deleterious effects of stress and depression on this region.</description><identifier>ISSN: 1180-4882</identifier><identifier>EISSN: 1488-2434</identifier><identifier>DOI: 10.1503/jpn.110185</identifier><identifier>PMID: 23425950</identifier><identifier>CODEN: JPNEEF</identifier><language>eng</language><publisher>Ottawa, ON: Canadian Medical Association</publisher><subject>Adult ; Adult and adolescent clinical studies ; Aspartate ; Aspartic Acid - analogs & derivatives ; Aspartic Acid - metabolism ; Biological and medical sciences ; Brain research ; Case-Control Studies ; Choline - metabolism ; Cost of Illness ; Cross-Sectional Studies ; Depression ; Depressive Disorder, Major - metabolism ; Development and progression ; Female ; Fundamental and applied biological sciences. Psychology ; Glutamate ; Glutamic Acid - metabolism ; Glutamine - metabolism ; Health aspects ; Hippocampus (Brain) ; Hippocampus - metabolism ; Humans ; Magnetic Resonance Spectroscopy - methods ; Major depressive disorder ; Male ; Medical Education ; Medical sciences ; Mental depression ; Metabolites ; Middle Aged ; Mood disorders ; Physiological aspects ; Psychiatry ; Psychoanalysis ; Psychology. Psychoanalysis. Psychiatry ; Psychology. Psychophysiology ; Psychopathology. Psychiatry ; Research Papers ; Studies</subject><ispartof>Journal of psychiatry & neuroscience, 2013-03, Vol.38 (2), p.107-116</ispartof><rights>Canadian Medical Association</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2013 Joule Inc.</rights><rights>Copyright Canadian Medical Association Mar 2013</rights><rights>2013 Canadian Medical Association 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c722t-e16708d536a279c30051e5258c3d7ef854b050ec08ec9acd2295a1ef20a1599d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581591/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581591/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27110084$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23425950$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Diego-Adeliño, Javier, MD</creatorcontrib><creatorcontrib>Portella, Maria J., PhD</creatorcontrib><creatorcontrib>Puigdemont, Dolors, MD</creatorcontrib><creatorcontrib>Pérez-Egea, Rosario, MD</creatorcontrib><creatorcontrib>Pérez, Víctor, MD, PhD</creatorcontrib><creatorcontrib>Gómez-Ansón, Beatriz, MD, PhD</creatorcontrib><creatorcontrib>López-Moruelo, Olga, BSc</creatorcontrib><creatorcontrib>Serra-Blasco, Maria, BSc</creatorcontrib><creatorcontrib>Vives, Yolanda, PhD</creatorcontrib><title>Hippocampal abnormalities of glutamate/glutamine, N -acetylaspartate and choline in patients with depression are related to past illness burden</title><title>Journal of psychiatry & neuroscience</title><addtitle>J Psychiatry Neurosci</addtitle><description>Background Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness. The aim of our study was to investigate metabolite abnormalities in the hippocampus associated with past depressive illness burden. Methods Glutamate/glutamine (Glx), N -acetylaspartate (NAA) and choline (Cho), potential markers of glial/neuronal integrity and membrane turnover, respectively, were measured in adults with depression and healthy controls using a 3 T magnetic resonance spectroscopy scanner. Voxels were placed in the head of the right and left hippocampus. We controlled for systematic differences resulting from volume-of-interest (VOI) tissue composition and total hippocampal volume. Results Our final sample comprised a total of 16 healthy controls and 52 adult patients with depression in different stages of the illness (20 treatment-resistant/chronic, 18 remitted-recurrent and 14 first-episode), comparable for age and sex distribution. Patients with treatment-resistant/chronic and remitted-recurrent depression had significantly lower levels of Glx and NAA than controls, especially in the right hippocampal region ( p ≤ 0.025). Diminished levels of Glx were correlated with longer illness duration (left VOI r = −0.34, p = 0.01). By contrast, Cho levels were significantly higher in patients with treatment-resistant/chronic depression than those with first-episode depression or controls in the right and left hippocampus (up to 19% higher; all p ≤ 0.025) and were consistently related to longer illness duration (right VOI r = 0.30, p = 0.028; left VOI r = 0.38, p = 0.004) and more previous episodes (right VOI r = 0.46, p = 0.001; left VOI r = 0.44, p = 0.001). Limitations The cross-sectional design and the inclusion of treated patients are the main limitations of the study. Conclusion Our results support that metabolite alterations within the hippocampus are more pronounced in patients with a clinical evolution characterized by recurrences and/or chronicity and add further evidence to the potential deleterious effects of stress and depression on this region.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aspartate</subject><subject>Aspartic Acid - analogs & derivatives</subject><subject>Aspartic Acid - metabolism</subject><subject>Biological and medical sciences</subject><subject>Brain research</subject><subject>Case-Control Studies</subject><subject>Choline - metabolism</subject><subject>Cost of Illness</subject><subject>Cross-Sectional Studies</subject><subject>Depression</subject><subject>Depressive Disorder, Major - metabolism</subject><subject>Development and progression</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glutamate</subject><subject>Glutamic Acid - metabolism</subject><subject>Glutamine - metabolism</subject><subject>Health aspects</subject><subject>Hippocampus (Brain)</subject><subject>Hippocampus - metabolism</subject><subject>Humans</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Major depressive disorder</subject><subject>Male</subject><subject>Medical Education</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Metabolites</subject><subject>Middle Aged</subject><subject>Mood disorders</subject><subject>Physiological aspects</subject><subject>Psychiatry</subject><subject>Psychoanalysis</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychology. Psychophysiology</subject><subject>Psychopathology. Psychiatry</subject><subject>Research Papers</subject><subject>Studies</subject><issn>1180-4882</issn><issn>1488-2434</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqVk8Fu1DAQhiMEoqVw4QGQBQIBIq3txE1yQaoqoJUqkCicrVlnsuvi2KmdFPoUvDKz2tLuor0gH2Jnvvk91syfZU8F3xeKFwcXg98Xgota3ct2RVnXuSyL8j7tRc1zOsud7FFKF5xzyYV6mO3IopSqUXw3-31ihyEY6AdwDGY-xB6cHS0mFjo2d9MIPYx4sNpZj-_YZ5aDwfHaQRogjhRl4FtmFsFRnFnPBiABPyb2044L1uIQMSUbPIOILKKjlJaNgbg0MuucpzCbTbFF_zh70IFL-OTmu5d9__jh2_FJfvbl0-nx0VluKinHHMVhxetWFYcgq8YUnCuBSqraFG2FXa3KGVccDa_RNGBaKRsFAjvJQaimaYu97P1Kd5hmPbaGyo3g9BBtD_FaB7B6M-LtQs_DlS5UTQqCBF7fCMRwOWEadW-TQefAY5iSFoWQolqWSeiLf9CLMEVPzyNKFbIqD5s1ag4OtfVdoHvNUlQfFZLXpeJ1Q1S-hZqjRyoyeOws_d7gn2_hzWAv9Tq0vwWi1WJvzVbVNxsJxIz4a5zDlJI-Pf_6H-znTfbVGrtAcOMiBRo9Gp60Cb5dgSaGlCJ2t50TXC9NockUemUKgp-t9_oW_esCAl7eAJAMuC6CNzbdcRUJ0c13Q4M0mVcWozY08pZSfuA1pruu6iQ11-dL_y3tR11eWk8VfwCQcSYY</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>de Diego-Adeliño, Javier, MD</creator><creator>Portella, Maria J., PhD</creator><creator>Puigdemont, Dolors, MD</creator><creator>Pérez-Egea, Rosario, MD</creator><creator>Pérez, Víctor, MD, PhD</creator><creator>Gómez-Ansón, Beatriz, MD, PhD</creator><creator>López-Moruelo, Olga, BSc</creator><creator>Serra-Blasco, Maria, BSc</creator><creator>Vives, Yolanda, PhD</creator><general>Canadian Medical Association</general><general>Joule Inc</general><general>CMA Impact, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130301</creationdate><title>Hippocampal abnormalities of glutamate/glutamine, N -acetylaspartate and choline in patients with depression are related to past illness burden</title><author>de Diego-Adeliño, Javier, MD ; Portella, Maria J., PhD ; Puigdemont, Dolors, MD ; Pérez-Egea, Rosario, MD ; Pérez, Víctor, MD, PhD ; Gómez-Ansón, Beatriz, MD, PhD ; López-Moruelo, Olga, BSc ; Serra-Blasco, Maria, BSc ; Vives, Yolanda, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c722t-e16708d536a279c30051e5258c3d7ef854b050ec08ec9acd2295a1ef20a1599d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aspartate</topic><topic>Aspartic Acid - analogs & derivatives</topic><topic>Aspartic Acid - metabolism</topic><topic>Biological and medical sciences</topic><topic>Brain research</topic><topic>Case-Control Studies</topic><topic>Choline - metabolism</topic><topic>Cost of Illness</topic><topic>Cross-Sectional Studies</topic><topic>Depression</topic><topic>Depressive Disorder, Major - metabolism</topic><topic>Development and progression</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glutamate</topic><topic>Glutamic Acid - metabolism</topic><topic>Glutamine - metabolism</topic><topic>Health aspects</topic><topic>Hippocampus (Brain)</topic><topic>Hippocampus - metabolism</topic><topic>Humans</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Major depressive disorder</topic><topic>Male</topic><topic>Medical Education</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Metabolites</topic><topic>Middle Aged</topic><topic>Mood disorders</topic><topic>Physiological aspects</topic><topic>Psychiatry</topic><topic>Psychoanalysis</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychology. Psychophysiology</topic><topic>Psychopathology. Psychiatry</topic><topic>Research Papers</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Diego-Adeliño, Javier, MD</creatorcontrib><creatorcontrib>Portella, Maria J., PhD</creatorcontrib><creatorcontrib>Puigdemont, Dolors, MD</creatorcontrib><creatorcontrib>Pérez-Egea, Rosario, MD</creatorcontrib><creatorcontrib>Pérez, Víctor, MD, PhD</creatorcontrib><creatorcontrib>Gómez-Ansón, Beatriz, MD, PhD</creatorcontrib><creatorcontrib>López-Moruelo, Olga, BSc</creatorcontrib><creatorcontrib>Serra-Blasco, Maria, BSc</creatorcontrib><creatorcontrib>Vives, Yolanda, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of psychiatry & neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Diego-Adeliño, Javier, MD</au><au>Portella, Maria J., PhD</au><au>Puigdemont, Dolors, MD</au><au>Pérez-Egea, Rosario, MD</au><au>Pérez, Víctor, MD, PhD</au><au>Gómez-Ansón, Beatriz, MD, PhD</au><au>López-Moruelo, Olga, BSc</au><au>Serra-Blasco, Maria, BSc</au><au>Vives, Yolanda, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hippocampal abnormalities of glutamate/glutamine, N -acetylaspartate and choline in patients with depression are related to past illness burden</atitle><jtitle>Journal of psychiatry & neuroscience</jtitle><addtitle>J Psychiatry Neurosci</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>38</volume><issue>2</issue><spage>107</spage><epage>116</epage><pages>107-116</pages><issn>1180-4882</issn><eissn>1488-2434</eissn><coden>JPNEEF</coden><abstract>Background Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness. The aim of our study was to investigate metabolite abnormalities in the hippocampus associated with past depressive illness burden. Methods Glutamate/glutamine (Glx), N -acetylaspartate (NAA) and choline (Cho), potential markers of glial/neuronal integrity and membrane turnover, respectively, were measured in adults with depression and healthy controls using a 3 T magnetic resonance spectroscopy scanner. Voxels were placed in the head of the right and left hippocampus. We controlled for systematic differences resulting from volume-of-interest (VOI) tissue composition and total hippocampal volume. Results Our final sample comprised a total of 16 healthy controls and 52 adult patients with depression in different stages of the illness (20 treatment-resistant/chronic, 18 remitted-recurrent and 14 first-episode), comparable for age and sex distribution. Patients with treatment-resistant/chronic and remitted-recurrent depression had significantly lower levels of Glx and NAA than controls, especially in the right hippocampal region ( p ≤ 0.025). Diminished levels of Glx were correlated with longer illness duration (left VOI r = −0.34, p = 0.01). By contrast, Cho levels were significantly higher in patients with treatment-resistant/chronic depression than those with first-episode depression or controls in the right and left hippocampus (up to 19% higher; all p ≤ 0.025) and were consistently related to longer illness duration (right VOI r = 0.30, p = 0.028; left VOI r = 0.38, p = 0.004) and more previous episodes (right VOI r = 0.46, p = 0.001; left VOI r = 0.44, p = 0.001). Limitations The cross-sectional design and the inclusion of treated patients are the main limitations of the study. Conclusion Our results support that metabolite alterations within the hippocampus are more pronounced in patients with a clinical evolution characterized by recurrences and/or chronicity and add further evidence to the potential deleterious effects of stress and depression on this region.</abstract><cop>Ottawa, ON</cop><pub>Canadian Medical Association</pub><pmid>23425950</pmid><doi>10.1503/jpn.110185</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1180-4882 |
| ispartof | Journal of psychiatry & neuroscience, 2013-03, Vol.38 (2), p.107-116 |
| issn | 1180-4882 1488-2434 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3581591 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Adult and adolescent clinical studies Aspartate Aspartic Acid - analogs & derivatives Aspartic Acid - metabolism Biological and medical sciences Brain research Case-Control Studies Choline - metabolism Cost of Illness Cross-Sectional Studies Depression Depressive Disorder, Major - metabolism Development and progression Female Fundamental and applied biological sciences. Psychology Glutamate Glutamic Acid - metabolism Glutamine - metabolism Health aspects Hippocampus (Brain) Hippocampus - metabolism Humans Magnetic Resonance Spectroscopy - methods Major depressive disorder Male Medical Education Medical sciences Mental depression Metabolites Middle Aged Mood disorders Physiological aspects Psychiatry Psychoanalysis Psychology. Psychoanalysis. Psychiatry Psychology. Psychophysiology Psychopathology. Psychiatry Research Papers Studies |
| title | Hippocampal abnormalities of glutamate/glutamine, N -acetylaspartate and choline in patients with depression are related to past illness burden |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A15%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hippocampal%20abnormalities%20of%20glutamate/glutamine,%20N%20-acetylaspartate%20and%20choline%20in%20patients%20with%20depression%20are%20related%20to%20past%20illness%20burden&rft.jtitle=Journal%20of%20psychiatry%20&%20neuroscience&rft.au=de%20Diego-Adeli%C3%B1o,%20Javier,%20MD&rft.date=2013-03-01&rft.volume=38&rft.issue=2&rft.spage=107&rft.epage=116&rft.pages=107-116&rft.issn=1180-4882&rft.eissn=1488-2434&rft.coden=JPNEEF&rft_id=info:doi/10.1503/jpn.110185&rft_dat=%3Cgale_pubme%3EA320845089%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1353274690&rft_id=info:pmid/23425950&rft_galeid=A320845089&rft_els_id=1_s2_0_S1180488213500205&rfr_iscdi=true |